SLC22A23

Across TCGA cell cohorts, SLC22A23 mutation is significantly associated with the drug of many other genes, with 37 significant associations in total. LARGE_INTESTINE shows the largest number of these associations.

The most reproducible SLC22A23-associated genes across cancer lineages are Alisertib, RO-3306, and Niraparib. Each is linked with SLC22A23 in more than 1 cancer types. Because this analysis shows association rather than direction, both SLC22A23-to-partner and partner-to-SLC22A23 results are reported.

Each partner links to its own Q-omics profile. The box plot shows the strongest example, Alisertib grouped by SLC22A23-low versus SLC22A23-high in LARGE_INTESTINE.

mutation associated genes by consensus

Ranked by combined sampling and lineage consensus. X-score (SLC22A23→partner) and Y-score (partner→SLC22A23) are standardized regression coefficients; both directions are reported because the association is undirected. p-values are from the association test.

Lineage	Partner gene	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
LARGE_INTESTINE	Alisertib →	+0.924	+3.061	.004	.010	3	1
LARGE_INTESTINE	RO-3306 →	+0.555	+2.807	.030	.046	3	1
LARGE_INTESTINE	Niraparib →	+0.460	+2.700	.003	.030	3	1
LARGE_INTESTINE	50869 →	+0.405	+3.064	.034	.009	3	1
LARGE_INTESTINE	BPD-00008900 →	+0.435	+2.655	.030	.044	3	1
LARGE_INTESTINE	CP724714 →	+0.338	+2.874	.034	.021	3	1

Each partner links to its Q-omics profile. Showing the 6 strongest of 37 associations by consensus.

Alisertib by SLC22A23 expression — LARGE_INTESTINE

Explore this box plot interactively →